Accenture has made a strategic investment in Ryght AI, a platform provider focused on modernizing how clinical research is designed and executed across the life sciences industry, as enterprise demand for agentic AI continues to accelerate in drug development and clinical trials.
The investment was made through Accenture Ventures and is aimed at helping life sciences and clinical research organizations shorten development timelines and bring new treatments to patients faster by combining agentic AI capabilities with enterprise-grade technology and data solutions. Financial terms of the investment were not disclosed.
Clinical trials have grown increasingly complex in recent years, with sponsors facing mounting challenges related to site selection, trial feasibility, and patient enrollment. These challenges have contributed to longer study startup timelines and rising development costs, as manual and fragmented processes often add weeks or months to trial execution. As a result, promising therapies can face significant delays before reaching patients.
Ryght AI is addressing these bottlenecks through its AI Site Twin platform, which creates dynamic digital replicas of clinical research sites worldwide. These site-level models incorporate historical performance data, patient demographics, regulatory considerations, and real-time operational insights. By leveraging this data, sponsors and contract research organizations can more efficiently identify suitable trial sites, improve enrollment forecasting, and streamline site activation workflows.
Through the collaboration, Accenture will combine its industry expertise, technology services, and data engineering capabilities with Ryght AI’s domain-specific agentic AI platform. The joint effort is designed to help life sciences organizations accelerate three critical stages of drug development: trial feasibility assessment, site selection, and patient recruitment. The companies expect the integration of agentic AI into these workflows to improve decision-making, operational efficiency, and trial outcomes at scale.
The investment in Ryght AI builds on Accenture’s broader strategy of backing emerging biotechnology and AI-driven platforms that aim to transform clinical research and drug discovery. Recent Accenture investments include companies such as 1910 Genetics, Turbine, and Earli, each focused on advancing AI-enabled approaches across different aspects of biopharmaceutical research and development.
Ryght AI’s platform is SOC Type 2 compliant and is designed to enable real-time collaboration between sponsors, contract research organizations, and clinical research sites. The company positions its technology as a way to reduce friction across study startup processes while enabling more data-driven planning and execution throughout the clinical trial lifecycle.
KEY QUOTES:
“Generative and agentic AI are transforming the foundation of clinical research. With our investment in Ryght AI, we’re giving our life sciences clients the ability to fully leverage operational and scientific data and bring life-changing therapies to market faster, more efficiently and with greater precision.”
Petra Jantzer, PhD, Senior Managing Director And Global Lead Of Life Sciences, Accenture
“This partnership allows Ryght AI to extend the impact and adoption of our technology to a global scale. Together, we can help life science companies reimagine how clinical trials are planned, launched and managed— accelerating the journey from discovery to treatment.”
Simon Arkell, Chief Executive Officer, Ryght AI
